185 related articles for article (PubMed ID: 26954374)
1. A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.
Diao Y; Liu J; Ma Y; Su M; Zhang H; Hao X
Cancer Biol Ther; 2016 May; 17(5):498-506. PubMed ID: 26954374
[TBL] [Abstract][Full Text] [Related]
2. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
5. Development of elastin-like polypeptide for targeted specific gene delivery in vivo.
Yi A; Sim D; Lee YJ; Sarangthem V; Park RW
J Nanobiotechnology; 2020 Jan; 18(1):15. PubMed ID: 31952530
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
Liu HY; Yu X; Liu H; Wu D; She JX
Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
[TBL] [Abstract][Full Text] [Related]
7. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.
Hao Z; Fan W; Hao J; Wu X; Zeng GQ; Zhang LJ; Nie SF; Wang XD
Drug Deliv; 2016; 23(3):874-81. PubMed ID: 24892627
[TBL] [Abstract][Full Text] [Related]
8. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
9. Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptide-dsRNA binding domain.
Li H; Zheng X; Koren V; Vashist YK; Tsui TY
Int J Pharm; 2014 Jul; 469(1):206-13. PubMed ID: 24768403
[TBL] [Abstract][Full Text] [Related]
10. Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Xu X; Xia X; Wang H; Li L; Dong W; Ma P; Liu Y
Int J Pharm; 2016 Jun; 506(1-2):158-73. PubMed ID: 27106526
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
12. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery.
Crombez L; Morris MC; Heitz F; Divita G
Methods Mol Biol; 2011; 764():59-73. PubMed ID: 21748633
[TBL] [Abstract][Full Text] [Related]
13. PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo.
Zhang T; Zhang X; Ding K; Yang K; Zhang Z; Xu Y
J Surg Oncol; 2010 May; 101(6):513-9. PubMed ID: 20191609
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
15. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
17. VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide.
Lee YW; Hwang YE; Lee JY; Sohn JH; Sung BH; Kim SC
J Microbiol Biotechnol; 2018 Mar; 28(3):367-374. PubMed ID: 29316746
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity.
Shen J; Liu J; Long Y; Miao Y; Su M; Zhang Q; Han H; Hao X
Acta Biochim Biophys Sin (Shanghai); 2009 Mar; 41(3):223-30. PubMed ID: 19280061
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of siRNA transfection by the optimization of fatty acid length and histidine content in the CPP.
Porosk L; Arukuusk P; Põhako K; Kurrikoff K; Kiisholts K; Padari K; Pooga M; Langel Ü
Biomater Sci; 2019 Sep; 7(10):4363-4374. PubMed ID: 31411219
[TBL] [Abstract][Full Text] [Related]
20. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
